Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Famitinib in FGFR2-altered intrahepatic cholangiocarcinoma after first-line failure
CTR20201325Phase 2Terminated
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of famitinib in intrahepatic cholangiocarcinoma (ICC), sponsored by Hengrui Therapeutics. Started Jul 2020; status: terminated.
02
Drugs
famitinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on CTR20201325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201325.